Ibrutinib and Acalabrutinib Use and Risk of Atrial Fibrillation in Patients With Chronic B-cell Malignancies

NCT06561243 · clinicaltrials.gov ↗

ACTIVE_NOT_RECRUITING

Status

15000

Enrollment

OTHER

Sponsor class

Conditions

Chronic B-cell Malignancies
BTK Inhibitors
Cardiovascular Diseases

Interventions

DRUG: BTK inhibitor (Ibrutinib or Acalabrutinib)

Sponsor

University Hospital, Caen